NEWS

June 26, 2020

Chiasma Announces FDA Approval of MYCAPSSA® (Octreotide) Capsules, the First and Only Oral Somatostatin Analog

June 22, 2020

Karyopharm Announces FDA Approval of XPOVIO® (selinexor) for the Treatment of Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)

June 9, 2020

Albireo Announces Two Financing Transactions to Extend Cash Runway Into the Beginning of 2022

June 1, 2020

First Meeting with Ted Seides: Interview with Clarke Futch – HealthCare Royalty Partners

May 12, 2020

COVID-19 Private Financing

April 8, 2020

Chiasma Enters Into Revenue Interest Financing Agreement for up to $75 Million with Healthcare Royalty Partners

April 2, 2020

RedHill Biopharma Completes Acquisition of Movantik^® from AstraZeneca

March 2, 2020

Karyopharm Announces Phase 3 BOSTON Study Meets Primary Endpoint with Significant Increase in Progression-Free Survival in Patients with Multiple Myeloma Following One to Three Prior Lines of Therapy

February 25, 2020

RedHill Biopharma Acquires Rights to Movantik^® from AstraZeneca

February 25, 2020

RedHill Biopharma Enters $115 Million Non-Dilutive Financing Agreement with HealthCare Royalty Partners